SARS-CoV-2 501Y.V2 (B.1.351) elicits cross-reactive neutralizing antibodies
Moyo-Gwete, T.; Madzivhandila, M.; Makhado, Z.; Ayres, F.; Mhlanga, D.; Oosthuysen, B.; Lambson, B.; Kgagudi, P.; Tegally, H.; Iranzadeh, A.; Doolabh, D.; Tyers, L.; Chinhoyi, L.; Mennen, M.; Skelem, S.; Wibmer, C. K.; Bhiman, J.; Ueckermann, V.; Rossouw, T.; Boswell, M.; de Oliveira, T.; Williamson, C.; Burgers, W.; Ntusi, N.; Morris, L.; Moore, P.
Show abstract
Neutralization escape by SARS-CoV-2 variants, as has been observed in the 501Y.V2 (B.1.351) variant, has impacted the efficacy of first generation COVID-19 vaccines. Here, the antibody response to the 501Y.V2 variant was examined in a cohort of patients hospitalized with COVID-19 in early 2021 - when over 90% of infections in South Africa were attributed to 501Y.V2. Robust binding and neutralizing antibody titers to the 501Y.V2 variant were detected and these binding antibodies showed high levels of cross-reactivity for the original variant, from the first wave. In contrast to an earlier study where sera from individuals infected with the original variant showed dramatically reduced potency against 501Y.V2, sera from 501Y.V2-infected patients maintained good cross-reactivity against viruses from the first wave. Furthermore, sera from 501Y.V2-infected patients also neutralized the 501Y.V3 (P.1) variant first described in Brazil, and now circulating globally. Collectively these data suggest that the antibody response in patients infected with 501Y.V2 has a broad specificity and that vaccines designed with the 501Y.V2 sequence may elicit more cross-reactive responses.
Matching journals
The top 6 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- ChAdOx1 nCoV-19 (AZD1222) vaccine elicits monoclonal antibodies with potent cross-neutralizing activity against SARS-CoV-2 viral variants 96%
- LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants 96%
- Spike-specific IgG4 generated post BNT162b2 mRNA vaccination is inhibitory when directly competing with functional IgG subclasses 96%
Similar papers in this journal
- Accelerated SARS-CoV-2 intrahost evolution leading to distinct genotypes during chronic infection 96%
- Asymptomatic and symptomatic SARS-CoV-2 infections elicit polyfunctional antibodies 95%
- Antibody escape drives emergence of diverse spike haplotypes resembling variants of concern in persistent SARS-CoV-2 infections 95%
Similar papers in this journal
- A combination of potently neutralizing monoclonal antibodies isolated from an Indian convalescent donor protects against the SARS-CoV-2 delta variant 95%
- Homologous Ad26.COV2.S vaccination results in reduced boosting of humoral responses in hybrid immunity, but elicits antibodies of similar magnitude regardless of prior infection 95%
- Structure selected RBM immunogens prime polyclonal memory responses that neutralize SARS-CoV-2 variants of concern 95%
Similar papers in this journal
- Potent Human Broadly SARS-CoV-2 Neutralizing IgA and IgG Antibodies Effective Against Omicron BA.1 and BA.2 95%
- Repertoire, function, and structure of serological antibodies induced by the R21/Matrix-M malaria vaccine 95%
- Antibody potency, effector function and combinations in protection from SARS-CoV-2 infection in vivo 95%
Similar papers in this journal
- Functional characterization and lineage analysis of broadly neutralizing human antibodies against dengue virus identified by single B cell transcriptomics 95%
- Reduced antibody cross-reactivity following infection with B.1.1.7 than with parental SARS-CoV-2 strains 95%
- Mapping person-to-person variation in viral mutations that escape polyclonal serum targeting influenza hemagglutinin 95%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.